Results come after positive results from a trial among people with idiopathic pulmomary disease.

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.

In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...

Key Progressive pulmonary fibrosis Therapie s: Nerandomilast (BI 1015550), BMS-986278, AP01, Inhaled Treprostinil, HEC585, ENV-101, and others ...

Pulmonary fibrosis and respiratory innovation Boehringer Ingelheim also reported positive Phase 3 results from the FIBRONEER-ILD trial of nerandomilast in progressive pulmonary fibrosis.

Find latest technology news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

From waterproof totes to mesh carryalls, the right beach bag can make summer fun more convenient.